## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE TECHNOLOGY APPRAISAL PROGRAMME

## Equality impact assessment - Scoping

## Cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping
	process (draft scope consultation and scoping workshop discussion),
	and, if so, what are they?

Comments were received at consultation which stated that there was often difficulty in accessing treatment as an adult, particularly where drugs were not licensed for adults – despite there being no difference in the condition.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The appraisal for Dravet syndrome should consider the management of patients as they transition to adulthood.

3.	Has any change to the draft scope been agreed to highlight potential
	equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Technology Appraisals: Scoping

Equality impact assessment for the Single Technology Appraisal of cannabidiol for the adjuvant treatment of seizures associated with Dravet syndrome

Issue date: October 2018 1 of 2

No additional stakeholders were identified.

Approved by Associate Director (name): Melinda Goodall

Date: 26/10/2018

Technology Appraisals: Scoping Equality impact assessment for the Single Technology Appraisal of cannabidiol for the adjuvant treatment of seizures associated with Dravet syndrome

Issue date: October 2018 2 of 2